Drug intelligence / Profile preview

HWS0101

Development stage: Unknown
Lead developer: Jiangsu Kanion Pharmaceutical
Modality: Small Molecules
Administration: Topical

Overview

HWS0101 is an investigational small molecule therapeutic being developed by Jiangsu Kanion Pharmaceutical (Kanion) in collaboration with Huawe Medicine for the treatment of chronic venous leg ulcers (CVLU). The drug is specifically intended for patients whose ulcers are unresponsive to standard care and compression therapy. Currently in Phase 1 clinical development, HWS0101 is formulated for topical administration, likely as a cream or gel, to facilitate wound healing. Kanion holds the development and commercialization rights for the drug in China and Europe.

Beyond the preview

Go deeper on HWS0101.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HWS0101.

Explore the full profile